je.st
news
FDA Ad Comm backs AstraZeneca's lesinurad for gout-associated hyperuricemia
2015-10-26 03:18:05| Biotech - Topix.net
The FDA's Arthritis Advisory Committee votes 10-4 recommending approval of AstraZeneca's lesinurad 200 mg tablets, in combination with a xanthine oxidase inhibitor , for the treatment of hyperuricemia associated with gout. The FDA's date is December 29. Lesinurad inhibits a protein called urate transporter which is responsible for most of the renal reabsorption of uric acid.
Tags: comm
backs
fda
astrazenecas
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||